Download this White Paper to learn more.
Expanding into Europe, particularly when bringing a rare disease drug to market, can be a complex undertaking for international biotechs. This guide will help you implement the right regulatory strategy to make the process as swift and as smooth as possible.
For the estimated 36 million people and their families in Europe living with a rare disease, new treatments can offer hope for a better quality of life. Many international biotechs offering these treatments, however, may feel cautious about expanding into a market with a reputation for complexity. But with the appropriate strategies in place, European expansion is far from impossible.
In this free white paper, we explore how to design effective regulatory strategies for your rare disease drug. We break down some of the key elements of the European rare disease regulatory landscape, the role of the European Medicines Agency (EMA) and the importance of orphan designation.
You’ll also discover:
- How credible data will strengthen your application for orphan designation
- How to secure EMA approval, including through accelerated assessments
- What the anticipated changes and challenges in regulatory strategies are for rare disease drugs.
Offered Free by: Sciensus
See All Resources from: Sciensus
